Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 19% ± 4% | |
monocyte | 6 studies | 22% ± 3% | |
classical monocyte | 6 studies | 22% ± 8% | |
epithelial cell | 6 studies | 31% ± 18% | |
macrophage | 5 studies | 20% ± 3% | |
goblet cell | 4 studies | 20% ± 3% | |
GABAergic neuron | 3 studies | 35% ± 22% | |
dendritic cell | 3 studies | 25% ± 10% | |
transit amplifying cell | 3 studies | 25% ± 12% |
Insufficient scRNA-seq data for expression of TRIM25 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3296.23 | 1444 / 1445 | 100% | 25.84 | 183 / 183 |
intestine | 100% | 4015.23 | 965 / 966 | 100% | 23.87 | 527 / 527 |
stomach | 100% | 3384.96 | 359 / 359 | 100% | 23.38 | 285 / 286 |
uterus | 100% | 3557.66 | 170 / 170 | 100% | 20.94 | 457 / 459 |
lung | 100% | 6551.03 | 578 / 578 | 99% | 18.31 | 1148 / 1155 |
breast | 100% | 3561.67 | 459 / 459 | 99% | 21.04 | 1111 / 1118 |
ovary | 99% | 3131.80 | 179 / 180 | 100% | 19.91 | 429 / 430 |
skin | 100% | 5785.59 | 1809 / 1809 | 99% | 21.30 | 468 / 472 |
thymus | 100% | 3067.04 | 652 / 653 | 99% | 15.75 | 598 / 605 |
bladder | 100% | 3199.14 | 21 / 21 | 98% | 18.08 | 494 / 504 |
prostate | 100% | 2534.18 | 245 / 245 | 97% | 13.62 | 488 / 502 |
kidney | 100% | 2455.81 | 89 / 89 | 97% | 14.39 | 872 / 901 |
pancreas | 98% | 2434.78 | 321 / 328 | 99% | 13.20 | 176 / 178 |
liver | 100% | 4049.04 | 226 / 226 | 90% | 10.01 | 367 / 406 |
adrenal gland | 100% | 5154.40 | 257 / 258 | 87% | 9.18 | 200 / 230 |
brain | 84% | 1418.37 | 2212 / 2642 | 100% | 17.38 | 705 / 705 |
spleen | 100% | 10750.82 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.12 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.55 | 1 / 1 |
adipose | 100% | 4298.65 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 17589.68 | 926 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 16.44 | 78 / 80 |
lymph node | 0% | 0 | 0 / 0 | 97% | 19.05 | 28 / 29 |
blood vessel | 95% | 1870.62 | 1264 / 1335 | 0% | 0 | 0 / 0 |
heart | 94% | 1581.79 | 813 / 861 | 0% | 0 | 0 / 0 |
muscle | 93% | 1858.04 | 749 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033280 | Biological process | response to vitamin D |
GO_0043627 | Biological process | response to estrogen |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0045087 | Biological process | innate immune response |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0032880 | Biological process | regulation of protein localization |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0046597 | Biological process | negative regulation of viral entry into host cell |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0039529 | Biological process | RIG-I signaling pathway |
GO_0019076 | Biological process | viral release from host cell |
GO_0044790 | Biological process | suppression of viral release by host |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0006979 | Biological process | response to oxidative stress |
GO_0046596 | Biological process | regulation of viral entry into host cell |
GO_0002753 | Biological process | cytoplasmic pattern recognition receptor signaling pathway |
GO_0036503 | Biological process | ERAD pathway |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0016874 | Molecular function | ligase activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0039552 | Molecular function | RIG-I binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIM25 |
Protein name | E3 ubiquitin/ISG15 ligase TRIM25 (EC 6.3.2.n3) (Estrogen-responsive finger protein) (RING finger protein 147) (RING-type E3 ubiquitin transferase) (EC 2.3.2.27) (RING-type E3 ubiquitin transferase TRIM25) (Tripartite motif-containing protein 25) (Ubiquitin/ISG15-conjugating enzyme TRIM25) (Zinc finger protein 147) Tripartite motif containing 25 Alternative protein TRIM25 |
Synonyms | EFP ZNF147 RNF147 |
Description | FUNCTION: Functions as a ubiquitin E3 ligase and as an ISG15 E3 ligase . Involved in innate immune defense against viruses by mediating ubiquitination of RIGI and IFIH1 . Mediates 'Lys-63'-linked polyubiquitination of the RIGI N-terminal CARD-like region and may play a role in signal transduction that leads to the production of interferons in response to viral infection . Mediates 'Lys-63'-linked polyubiquitination of IFIH1 . Promotes ISGylation of 14-3-3 sigma (SFN), an adapter protein implicated in the regulation of a large spectrum signaling pathway . Mediates estrogen action in various target organs . Mediates the ubiquitination and subsequent proteasomal degradation of ZFHX3 . Plays a role in promoting the restart of stalled replication forks via interaction with the KHDC3L-OOEP scaffold and subsequent ubiquitination of BLM, resulting in the recruitment and retainment of BLM at DNA replication forks (By similarity). Plays an essential role in the antiviral activity of ZAP/ZC3HAV1; an antiviral protein which inhibits the replication of certain viruses. Mechanistically, mediates 'Lys-63'-linked polyubiquitination of ZAP/ZC3HAV1 that is required for its optimal binding to target mRNA . Mediates also the ubiquitination of various substrates implicated in stress granule formation, nonsense-mediated mRNA decay, nucleoside synthesis and mRNA translation and stability . . |
Accessions | ENST00000648772.1 L0R8K6 ENST00000572021.6 Q14258 I3L2W4 ENST00000682766.1 A0A3B3IUA7 ENST00000537230.3 ENST00000316881.9 |